Exact Sciences Corp. EXAS

NAS: EXAS | ISIN: US30063P1057   20/03/2026
104,91 USD (+0,95%)
(+0,95%)   20/03/2026

31 december 2025 · Smart Oncology: 5 Stocks Chasing the $317B Prize · Persbericht

20 november 2025 · Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments · Persbericht

19 maart 2025 · Sera Prognostics Announces Appointment Of Jeff Elliott To Its Board; Ryan Trimble And Marcus Wilson To Step Down · Persbericht

31 juli 2024 · TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology · Persbericht

7 januari 2024 · Exact Sciences Announces Preliminary Fourth Quarter 2023 Results · Persbericht

2 januari 2024 · Exact Sciences to participate in J.P. Morgan Healthcare Conference · Persbericht

7 december 2023 · Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings · Persbericht

1 november 2023 · Exact Sciences Announces Third-Quarter 2023 Results · Persbericht

1 november 2023 · Exact Sciences to participate in November investor conferences · Persbericht

22 oktober 2023 · Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection · Persbericht

21 oktober 2023 · Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress · Persbericht

9 oktober 2023 · Exact Sciences schedules third quarter 2023 earnings call · Persbericht

9 oktober 2023 · Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023 · Persbericht

1 september 2023 · Exact Sciences to participate in September investor conference · Persbericht

30 augustus 2023 · Exact Sciences Lab and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical Trials · Persbericht

21 augustus 2023 · Not a Wall, But an Obstacle Course: New Findings Reveal Why 45-Year-Olds Are Avoiding Colorectal Cancer Screenings · Persbericht

1 augustus 2023 · Exact Sciences Announces Second-Quarter 2023 Results · Persbericht

10 juli 2023 · Exact Sciences schedules second quarter 2023 earnings call · Persbericht

21 juni 2023 · Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations · Persbericht

20 juni 2023 · Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening · Persbericht

Mijn selecties